Mamidi N V, Rajasekhar A, Prabhakar M C, Krishna D R
University College of Pharmaceutical Sciences, Kakatiya University, Warangal, India.
Arzneimittelforschung. 1995 Sep;45(9):1029-31.
Tissue distribution and deposition characteristics of clofazimine (CAS 2030-63-9), an antileprotic drug in rats have been investigated following controlled sub-chronic administration (p.o.) for a period of 1-2 months. The drug was administered alone at a dose of 20 mg/kg body weight and in combination with rifampicin (CAS 13292-46-1) (20 mg/kg p.o.). Various tissues (liver, lung, spleen, small intestine, brain, heart, kidney, skin, stomach and subcutaneous fat) were analyzed for clofazimine in all the treated groups. High levels (range 0.9-3.6 mg/g of wet tissue) were observed in tissues having reticuloendothelial components. In other tissues the levels were relatively lower (range 3-114 micrograms/g of wet tissue). Histopathological studies revealed that clofazimine is deposited in many tissues in the form of reddish-orange crystals. Concomitant treatment with rifampicin did not significantly alter tissue distribution or deposition profile of clofazimine nor did it influence the histopathology.
在对大鼠进行为期1 - 2个月的对照亚慢性口服给药后，研究了抗麻风病药物氯法齐明（CAS 2030 - 63 - 9）在大鼠体内的组织分布和沉积特征。该药物单独以20 mg/kg体重的剂量给药，或与利福平（CAS 13292 - 46 - 1）（口服20 mg/kg）联合给药。对所有治疗组的各种组织（肝脏、肺、脾脏、小肠、大脑、心脏、肾脏、皮肤、胃和皮下脂肪）进行了氯法齐明分析。在具有网状内皮成分的组织中观察到高水平（范围为0.9 - 3.6 mg/g湿组织）。在其他组织中，水平相对较低（范围为3 - 114微克/g湿组织）。组织病理学研究表明，氯法齐明以红橙色晶体的形式沉积在许多组织中。与利福平联合治疗并未显著改变氯法齐明的组织分布或沉积情况，也未影响组织病理学。
